New GSK shingles vaccine off to strong start in key U.S. market

LONDON (Reuters) - GlaxoSmithKline's new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news